Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Vaccine. 2021 Oct 1;39(41):6037-6040. doi: 10.1016/j.vaccine.2021.09.012. Epub 2021 Sep 7.
Prenatal maternal physiological changes may cause severe COVID-19 among pregnant women. The Pfizer-BioNTech COVID-19 vaccine (BNT162b2 mRNA) has been shown to be highly effective and it is recommended for individuals aged ≥16 years, including pregnant women, although the vaccine has not been tested on the latter.
To study the association between prenatal Pfizer-BioNTech COVID-19 vaccination, pregnancy course and outcomes.
A retrospective cohort study was performed, including all women who delivered between January and June 2021 at Soroka University Medical Center, the largest birth center in Israel. Excluded were women diagnosed with COVID-19 in the past, multiple gestations or unknown vaccination status. Pregnancy, delivery and newborn complications were compared between women who received 1 or 2-dose vaccines during pregnancy and unvaccinated women. Multivariable models were used to adjust for background characteristics.
A total of 4,399 women participated in this study, 913 (20.8%) of which were vaccinated during pregnancy. All vaccinations occurred during second or third trimesters. As compared to the unvaccinated women, vaccinated women were older, more likely to conceive following fertility treatments, to have sufficient prenatal care, and of higher socioeconomic position. In both crude and multivariable analyses, no differences were found between the groups in pregnancy, delivery and newborn complications, including gestational age at delivery, incidence of small for gestational age and newborn respiratory complications.
Prenatal maternal COVID-19 vaccine has no adverse effects on pregnancy course and outcomes. These findings may help pregnant women and health care providers to make informed decision regarding vaccination.
孕妇的产前生理变化可能导致孕妇出现严重的 COVID-19 。辉瑞-生物科技公司的 COVID-19 疫苗（BNT162b2 mRNA）已被证明具有高度有效性，建议≥16 岁的个体接种，包括孕妇，尽管尚未对后者进行疫苗测试。
研究产前辉瑞-生物科技公司 COVID-19 疫苗接种与妊娠过程和结局之间的关联。
这是一项回顾性队列研究，纳入了 2021 年 1 月至 6 月期间在以色列最大的分娩中心索罗卡大学医学中心分娩的所有女性。排除了过去患有 COVID-19 的女性、多胎妊娠或疫苗接种状况未知的女性。比较了在妊娠期间接受 1 剂或 2 剂疫苗的女性与未接种疫苗的女性的妊娠、分娩和新生儿并发症。使用多变量模型调整背景特征。
共有 4399 名女性参与了这项研究，其中 913 名（20.8%）在妊娠期间接种了疫苗。所有疫苗接种均发生在第二或第三孕期。与未接种疫苗的女性相比，接种疫苗的女性年龄更大，更有可能通过生育治疗受孕，接受足够的产前保健，社会经济地位更高。在粗分析和多变量分析中，两组之间在妊娠、分娩和新生儿并发症方面均无差异，包括分娩时的胎龄、小于胎龄儿的发生率和新生儿呼吸并发症。
产前母体 COVID-19 疫苗对妊娠过程和结局没有不良影响。这些发现可能有助于孕妇和医疗保健提供者在接种疫苗方面做出明智的决策。
